Comparison of antifungal treatments for murine fusariosis

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 973-979

  Spellberg, Brad ^a,b   Schwartz, Julie ^c   Fu, Yue ^a,b   Avanesian, Valentina ^a   Adler Moore, Jill ^d   Edwards Jr , John E ^a,b   Ibrahim, Ashraf S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

^d CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

Author keywords

Antifungal therapy; Fusarium solani

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOPEPTIDE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BRAIN; DRUG COMBINATION; FUSARIUM; GROWTH, DEVELOPMENT AND AGING; KIDNEY; MALE; MICROBIOLOGY; MOUSE; MYCOSIS; NEUTROPENIA;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BRAIN; DRUG COMBINATIONS; FUSARIUM; KIDNEY; MALE; MICE; MICE, INBRED BALB C; MYCOSES; NEUTROPENIA; PEPTIDES, CYCLIC; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS;

EID: 33947187696     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl378     Document Type: Article

References (24)

1. Torres HA, Kontoyianis DP. Hyalohyphomycoses (other than aspergillosis and penicilliosis). In: Dismukes WE, Pappas PG, Sobel JD, eds. Clinical Mycology. New York: Oxford University Press, 2003; 252-70.
2. Zhang N, O'Donnell K, Sutton DA et al. Members of the Fusarium solani species complex that cause infections in both humans and plants are common in the environment. J Clin Microbiol 2006; 44 2186-90.
3. Diekema DJ, Messer SA, Hollis RJ et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623-6.
4. Nerkelun S, Kellermann S, Nenning H. [Acute blindness caused by fungal infection in chronic myeloid leukemia]. Klinische Monatsblatter fur Augenheilkunde 1997; 211: 272-4.
5. Viola MV. Acute leukemia and infection. JAMA 1967; 201: 923-6.
6. Bodey GP, Boktour M, Mays S et al. Skin lesions associated with Fusarium infection. J Am Acad Dermatol 2002; 47: 659-66.
7. Letscher-Bru V, Campos F, Waller J et al. Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient. J Clin Microbiol 2002; 40: 1100-2.
8. Mayayo E, Pujol I, Guarro J. Experimental pathogenicity of four opportunist Fusarium species in a murine model. J Med Microbiol 1999; 48: 363-6.
9. Guarro J, Pujol I, Mayayo E. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob Agents Chemother 1999; 43: 1256-7.
10. Graybill JR, Najvar LK, Gonzalez GM et al. Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother 2003; 51: 1373-6.
11. Shadomy S, McCay JA, Schwartz SI. Bioassay for hamycin and amphotericin B in serum and other biological fluids. Appl Microbiol 1969; 17 497-503.
12. Spellberg B, Fu Y, Edwards J,Jr et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49: 830-2.
13. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-6.
14. Pfaller MA, Marco F, Messer SA et al. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251-5.
15. Tawara S, Ikeda F, Maki K et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57-62.
16. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-7.
17. Ibrahim AS, Bowman JC, Avanessian V et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49: 721-7.
18. Ferrante MC, Meli R, Mattace Raso G et al. Effect of fumonisin B1 on structure and function of macrophage plasma membrane. Toxicol Lett 2002; 129: 181-7.
19. Spellberg B, Fu Y, Edwards JE Jr et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49: 830-2.
20. Spellberg BJ, Collins M, French SW et al. A phagocytic cell line markedly improves survival of infected neutropenic mice. J Leukoc Biol 2005; 78: 338-44.
21. Wiederhold NP, Kontoyiannis DP, Chi J et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-71.
22. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004; 48: 3407-11.
23. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24: 654-61.
24. Clemons KV, Espiritu M, Parmar R et al. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867-75.